Orthofix Medical Inc. (NASDAQ:OFIX) Receives Consensus Rating of “Hold” from Brokerages

Shares of Orthofix Medical Inc. (NASDAQ:OFIXGet Free Report) have received a consensus recommendation of “Hold” from the four ratings firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.00.

A number of equities research analysts have weighed in on OFIX shares. StockNews.com raised Orthofix Medical from a “sell” rating to a “hold” rating in a report on Wednesday. JMP Securities restated a “market perform” rating on shares of Orthofix Medical in a research note on Monday, April 22nd. Roth Mkm upgraded Orthofix Medical from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $15.00 to $20.00 in a research report on Wednesday. Finally, Roth Capital upgraded shares of Orthofix Medical from a “neutral” rating to a “buy” rating in a research report on Wednesday.

View Our Latest Stock Report on OFIX

Orthofix Medical Price Performance

Shares of NASDAQ OFIX opened at $14.90 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.54 and a quick ratio of 1.20. The company has a market cap of $557.41 million, a PE ratio of -3.60 and a beta of 1.06. The stock has a fifty day moving average price of $13.66 and a 200 day moving average price of $13.03. Orthofix Medical has a 1-year low of $9.57 and a 1-year high of $21.60.

Orthofix Medical (NASDAQ:OFIXGet Free Report) last released its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.01. Orthofix Medical had a negative net margin of 20.28% and a negative return on equity of 10.63%. The company had revenue of $200.42 million during the quarter. Sell-side analysts forecast that Orthofix Medical will post -1.51 EPS for the current year.

Institutional Trading of Orthofix Medical

Several large investors have recently bought and sold shares of the company. Gladius Capital Management LP raised its position in shares of Orthofix Medical by 55.2% during the 4th quarter. Gladius Capital Management LP now owns 2,841 shares of the medical device company’s stock worth $38,000 after purchasing an additional 1,010 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Orthofix Medical by 30.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,516 shares of the medical device company’s stock worth $101,000 after acquiring an additional 1,752 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new position in Orthofix Medical in the 3rd quarter valued at about $130,000. Teza Capital Management LLC acquired a new stake in shares of Orthofix Medical during the 3rd quarter worth about $133,000. Finally, Arizona State Retirement System purchased a new stake in shares of Orthofix Medical during the fourth quarter worth about $138,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

About Orthofix Medical

(Get Free Report

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

Further Reading

Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.